

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	4
-------	---	----	---

**Complete if Known**

<b>Application Number</b>	09/768,816
<b>Filing Date</b>	Jan. 23, 2001
<b>First Named Inventor</b>	Charbit, Suzy, et al
<b>Group Art Unit</b>	1614
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	H7708-002

RECEIVED  
MAY 01 2001  
TECH CENTER 1600/2900

**U.S. PATENT DOCUMENTS**

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner  
Signature

Nguyen K

Date  
Considered

07/24/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Trademark, DC 20231.**



Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+ #3

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/768,816		
		Filing Date	Jan. 23, 2001		
		First Named Inventor	Charbit, Suzy, et al.		
		Group Art Unit	1416		
		Examiner Name			
Sheet	2	of	4	Attorney Docket Number	H7708-002

RECEIVED

MAY 01 2001

TECH CENTER 1600/2900

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
WV		DOUGADOS M, NGUYEN M, BERDAH L, LEQUESNE M, MAZIÈRES B, VIGNON E 1999; Evaluation of the structural (radiological) effect of diacerein in osteoarthritis of the hip: a 3-year placebo controlled study. Osteoarthritis and Cart 7, Suppl A: 123.	
		LEQUESNE M, BRANDT K, BELLAMY N, MOSKOWITZ R, ET AL. 1994; Guidelines for testing slow acting drugs in osteoarthritis. J Rheum 21, Suppl 41: 65-73	
		MARCOLONGO R, FIORAVANTI A, ADAMI S, TOZZI E, ET AL. 1988; Efficacy and tolerability of diacerein in the treatment of osteoarthritis. Curr Ther Res 43: 878-87.	
		MARTEL-PELLETIER J, MINEAU F, JOLICOEUR FC, CLOUTIER JM, PELLETIER JP 1998; In vitro effects of diacerein and rhein on interleukin-1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. J Rheum 25:	
		NGUYEN M, DOUGADOS M, BERDAH L, AMOR B 1994; Diacerein in the treatment of osteoarthritis of the hip. Arthritis Rheum 37: 529-36.	
		PELLETIER JP, YARON M, COHEN P 1999; Treatment of osteoarthritis of the knee with diacerein: a double-blind, placebo controlled trial. Arthritis Rheum 42, Suppl. 9: S 295.	
		RONNINGEN H, LANGELAND N 1979; Indomethacin treatment in osteoarthritis of the hip joint. Acta Orthop Scand 50: 169-74.	
		HUSKISSON EC, ET AL. 1995; Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. J Rheum 22: 1941-6.	
		RASHAD S ET AL. 1989; Effect of non steroidal antiinflammatory drugs on the course of osteoarthritis. Lancet 2: 519-22.	
		TOWHEED T, HOCHBERG M 1997; A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the hip. J Rheum 24: 349-57.	
MS		DOHERTY M. 1989; "Chondroprotection" by non steroidal antiinflammatory drugs. Ann Rheum Dis 48: 619-21.	


Examiner Signature	<i>WV</i>	Date Considered	07/24/01
--------------------	-----------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

### Complete if Known

Application Number	09/768,816
Filing Date	Jan. 23, 2001
First Named Inventor	Charbit, Suzy, et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	H7708-002

RECEIVED

MAY 01 2001

TECH CENTER 1600/2900

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MP		PELLETIER JP, MARTEL-PELLETIER J 1989; The therapeutic effects of NSAID and corticosteroids in osteoarthritis: to be or not to be. J Rheum 16: 266-69.	
		VIGNON E ET AL. 1990; Cartilage degradative enzymes in human osteoarthritis: effect of a non steroidal antiinflammatory drug administered orally. Semin Arthritis Rheum 19 (suppl 1): 26-9.	
		BUCKLAND-WRIGHT JC ET AL. 1995; Quantitative microfocal radiography detects changes in OA knee joint space width in patients in placebo controlled trial of NSAID therapy. J Rheum 22: 937-43.	
		BRANDT K.D., SMITH G., KANG S.Y., MYERS S., O'CONNOR B., ALBRECHT M. 1997; Effects of diacerhein in an accelerated canine model of osteoarthritis. Osteoarthritis & Cartilage, 5: 438-49.	
		MCCARTHY D 1998; Nonsteroidal Anti-Inflammatory Drug-Related Gastrointestinal Toxicity: Definitions and Epidemiology. The American Journal of Medicine Vol 105 (5A).	
		MAZIÈRES B. 1997; Diacerhein in a post-contusive model of osteoarthritis. Structural results with <<prophylactic>> and <<curative>> regimens. Osteoarthritis & Cartilage, 5 (suppl.A): 7648.	
		MAZIÈRES B., BERDAH L. 1993; Effect of diacerheine (ART 50) on an experimental post-contusive model of OA. Osteoarthritis & Cartilage, 1: 47.	
		SMITH G. N., MYERS S. L., BRANDT K.D., MICKLER E. A., ALBRECHT M. E. 1999; Diacerhein treatment reduces the severity of osteoarthritis in the canine cruciate-deficiency model of osteoarthritis. Arthritis & Rheumatism, 42 : 545 - 54.	
		ARMSTRONG CP, BLOWER AL 1987; Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut; 28: 527 -32.	
		BJORKMAN DJ 1999; Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications. Am J Med 107 (6A): 3S-8S.	
		Drug and Therapeutic Bulletin 1987; Which NSAID? DTB 25: 81 - 4.	

Examiner  
Signature

*[Handwritten Signature]*


Date  
Considered

07/24/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

### Complete if Known

Application Number	09/768,816
Filing Date	Jan. 23, 2001
First Named Inventor	Charbit, Suzy, et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	H7708-002

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MW		HAWKEY J 1999; New Drug Classes: COX-2 Inhibitors. Lancet 353: 307-14.	
		HUSKISSON EC, ET AL. 1995; Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. J Rheumatol 22: 1941-6.	
		MARCOLONGO R, FIORAVANTI A, ADAMI S, TOZZI E, ET AL. 1988; Efficacy and tolerability of diacerein in the treatment of osteoarthritis. Curr Ther Res 43: 878-87.	
		TOWHEED TE, HOCHBERG MC 1997; A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the hip. J Rheumatol 24: 349-57.	
		VANE JR, BOTTING RM 1998; Overview: the mechanism of action of anti-inflammatory drugs. In: Clinical significance and potential of selective COX-2 inhibitors. Vane JR and Botting RM, Editors: 1-19. William Harvey Press, London.	
		DINARELLO CA 2000: The role of the Interleukin-1 receptor antagonist in blocking inflammation mediated by Interleukin-1. NEJM 343: 732-4.	
		DINARELLO CA 1991; Interleukin-1 and Interleukin-1 antagonist. Blood 77: 1627-52.	
MW		MOORE AR, GREENSLADE KJ, ALAM CAS, WILLOUGHBY DA 1998; Effects of diacerein on granuloma-induced cartilage breakdown in the mouse. Osteoarthritis And Cartilage 6: 19-23.	

Examiner  
Signature

Date  
Considered

07/24/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.